Glaukos submits NDA to US FDA for Epioxa for the treatment of keratoconus
Glaukos submitted its US FDA New Drug Application for Epioxa, a non-invasive corneal cross-linking therapy for keratoconus, with data from 2 Phase 3 trials. Epioxa aims to reduce procedure times, improve comfort, and shorten recovery, without requiring epithelium removal.
Highlighted Terms
Related News
Glaukos submits NDA to US FDA for Epioxa for the treatment of keratoconus
Glaukos submitted its US FDA New Drug Application for Epioxa, a non-invasive corneal cross-linking therapy for keratoconus, with data from 2 Phase 3 trials. Epioxa aims to reduce procedure times, improve comfort, and shorten recovery, without requiring epithelium removal.